Compare AstraZeneca plc (AZN) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs FuelCell Energy Inc — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while FuelCell Energy Inc trades at $21.67 (market cap $1.54B). The key difference: AstraZeneca plc is far larger — about 161.1× FuelCell Energy Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| AZN | FCEL | |
|---|---|---|
Market Cap | $248.14B | $1.54B |
Sector | Health | Industrials |
52-Week High | $209.48 | $36.01 |
52-Week Low | $147.06 | $3.92 |
Enterprise Value | $275.41B | $1.38B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
FCEL trades at $22.16, up 11.75% in the past 24 hours, but remains in a bearish technical trend. The company continues to post significant losses, with a net income margin of -132.41% in 2025, despite recent revenue growth to $158.16M. Analyst sentiment is divided with a 45% buy and 45% hold consensus, and a price target of $20.75. Recent news highlights partnerships and volatility within the hydrogen sector.
The outlook is clouded by persistent unprofitability and negative cash flow from operations, posing substantial risk. Upside potential hinges on successful commercialization of technology and sector tailwinds, but the stock faces headwinds from execution challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
